NORTH AUGUSTA, S.C. and DEVENS, Mass.– AmbioPharm, a worldwide leader in peptide API CDMO services, announces the acquisition of new, disruptive, peptide purification technology developed by YMC which leverages several of YMC’s patented twin-column purification processes. Twin-column chromatography or Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) is a continuous chromatographic process which collects a high purity center cut fraction and internally recycles mixed impurity/product-containing side fractions all while loading fresh feed and discarding impurities (see diagram).
This technology offers several advantages over traditional batch purification including:
- Higher peptide purity
- Increased yield
- Decreased solvent requirements
- Time savings
- Significant reduction of fraction collection, storage, QC, blending, and reprocessing
As a leader in peptide manufacturing and development, AmbioPharm is continuously upgrading equipment and technologies, especially those that can improve our capacity and sustainability. Using our expertise in peptide synthesis, we are able to tackle both simple and complex peptide projects with a proven history of success at research, clinical, and commercial scales.
